Page 173 - Genentech News Today

Polivy plus R-CHP is approved for the first-line treatment of patients with DLBCL NOS or HGBL who have an IPI score of 2 or greater.

Rebecca Carrier has developed a gut-on-a-chip model that has brought science closer to understanding the bodily effects of different foods.

/PRNewswire/ -- The highly-anticipated 2023 Edison Awards™ winners were revealed in Fort Myers, Florida, and the Industrial Technology Research Institute...

BioPharma

A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.The findings of the Neotorch study, presented during an ASCO Plenary Series session, also showed the addition of toripalimab (Junshi Biosciences) to

Researchers say the drug aflibercept performed better in a clinical trial than bevacizumab in helping wean people off treatments for wet age-related macular degeneration

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.The approval applies to adults with previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma who have an International Prognostic Index score of two or

– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin’s lymphoma in the U.S. –– POLARIX trial showed the Polivy combination reduced the risk of disease progression, relapse...

Dublin, April 20, 2023 (GLOBE NEWSWIRE) -- The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics...

Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS